Group 1 - The core viewpoint of the news is that Aipeng Medical experienced a decline in stock price, dropping by 5.02% to 34.47 CNY per share, with a trading volume of 419 million CNY and a turnover rate of 13.59%, resulting in a total market capitalization of 4.345 billion CNY [1] - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in the fields of pain management and nasal care [1] - The company's main business revenue composition includes pain management products at 61.52%, nasal and upper airway products at 30.55%, other products at 7.55%, and other businesses at 0.37% [1] Group 2 - According to data from the top ten heavy stocks of funds, Beixin Ruifeng Fund holds a significant position in Aipeng Medical, with its health living theme flexible allocation fund (001056) holding 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest heavy stock [2] - The fund, established on March 27, 2015, has a latest scale of 89.3779 million CNY, with a year-to-date return of 40.86%, ranking 1022 out of 8194 in its category, and a one-year return of 81.22%, ranking 687 out of 7962 [2] - The fund manager, Pang Wenjie, has been in position for 5 years and 88 days, with the fund's total asset scale at 17 million CNY, achieving a best return of 44.46% and a worst return of -44.25% during his tenure [3]

Group 1 - The core viewpoint of the news is that Aipeng Medical's stock has experienced a decline of 5.02%, with a current price of 34.47 CNY per share and a total market capitalization of 4.345 billion CNY [1] - Aipeng Medical, established on October 30, 2001, specializes in the development, production, and sales of medical devices in the pain management and nasal care sectors [1] - The company's revenue composition includes 61.52% from pain management products, 30.55% from nasal and upper airway products, 7.55% from other products, and 0.37% from other businesses [1] Group 2 - Among the top circulating shareholders of Aipeng Medical, Huaxia Fund's Huaxia Innovation Future Mixed Fund (LOF) has recently entered the top ten, holding 589,700 shares, which is 0.67% of the circulating shares [2] - The Huaxia Innovation Future Mixed Fund (LOF) was established on October 13, 2020, with a latest scale of 2.265 billion CNY and has achieved a year-to-date return of 33.22% [2] - The fund's performance over the past year shows a return of 57.97%, ranking 1810 out of 7962 in its category, while it has experienced a cumulative loss of 31.38% since inception [2]

Group 1 - The stock price of Aipeng Medical reached 36.29 yuan as of August 25, 2025, with an increase of 2.23 yuan, representing a rise of 6.55% from the previous trading day [1] - The company opened at 35.00 yuan, with a highest price of 37.50 yuan and a lowest price of 34.40 yuan, achieving a trading volume of 220,500 lots and a total transaction value of 791 million yuan [1] - Aipeng Medical's main business focuses on medical devices, including sectors such as robotics, specialized and innovative technologies, and influenza [1] Group 2 - The company recently established a wholly-owned subsidiary, Aipeng Zhiyuan Brain Science Technology (Shanghai) Co., Ltd., with a registered capital of 10 million yuan, engaging in artificial intelligence application system integration, intelligent unmanned aerial vehicles, and robotics sales [1] - Aipeng Medical has partnered with the Children's Hospital affiliated with Fudan University to establish a "Brain-Computer Interface Technology Behavioral Therapy Joint Laboratory," further expanding the application of brain-computer interface technology in the medical field [1] Group 3 - On August 25, Aipeng Medical saw a net inflow of main funds amounting to 39.64 million yuan, accounting for 1.33% of its circulating market value [1] - Over the past five days, the main funds experienced a net outflow of 19.60 million yuan, representing 0.66% of the circulating market value [1]

人民财讯8月23日电，8月21日上午，复旦大学附属儿科医院与爱朋医疗（300753）正式签署合作协议， 共同成立"脑机接口技术行为治疗联合实验室"。爱朋医疗董事长王凝宇在公司介绍中强调，作为一家深 耕医疗器械领域的上市公司，爱朋始终坚持围绕临床需求开展技术创新，基于急慢性疼痛管理、鼻腔上 气道轻诊疗的双轨并行的扎实基础上，重点介入脑机接口赛道，布局脑机接口在医疗健康领域中的应 用，尤其聚焦精准麻醉与测痛止痛、儿童注意力缺陷多动障碍(ADHD)、顽固性失眠等方向。公司成立 了"人工智能与脑机工程研究院"，组建跨学科团队，开发了脑机接口与AI结合的多模态行为干预系统。 ...

资金流向方面，当日主力资金净流入584.11万元，占流通市值的0.2%。近五个交易日主力资金累计净流 出12857.5万元，占流通市值的4.4%。 爱朋医疗最新股价为35.42元，较前一交易日上涨0.15元。当日开盘价为35.29元，最高触及36.21元，最 低下探34.69元，成交量为135586手，成交金额达4.81亿元。 该公司属于医疗器械行业，同时涉及机器人概念、专精特新等板块。爱朋医疗是一家专注于医疗器械研 发、生产和销售的企业。 8月19日早盘，爱朋医疗出现快速反弹走势，5分钟内涨幅超过2%。截至9点36分，股价报35.42元，成 交金额4802.54万元。 风险提示：市场有风险，投资需谨慎。 来源：金融界 ...

Group 1 - The stock price of Aipeng Medical showed a downward trend on August 15, closing at 35.93 yuan, a decrease of 2.12% from the previous trading day [1] - The intraday high reached 37.40 yuan, while the low fell to 35.70 yuan, resulting in an overall fluctuation of 4.63% throughout the day [1] - The trading volume for the day was 197,300 hands, with a total transaction amount of 712 million yuan, and a turnover rate of 23.94% [1] Group 2 - Aipeng Medical's main business includes the research, production, and sales of medical devices, covering multiple medical fields [1] - As a high-tech enterprise in Jiangsu Province, Aipeng Medical holds a certain influence in its niche market [1] Group 3 - On August 15, there was a net outflow of 81.4373 million yuan from the main funds, accounting for 2.75% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 44.5677 million yuan, representing 1.5% of the circulating market value [1] - A rapid decline was observed in the early trading session, with a drop of over 2% within five minutes [1]

证券之星消息，8月14日医疗器械板块较上一交易日下跌2.16%，利德曼领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300289 | 利德曼 | 10.06 | -11.21% | 106.05万 | | 10.85 Z | | 300981 | 中红医疗 | 16.00 | -9.91% | 26.13万 | | 4.31亿 | | 688677 | 海泰新光 | 45.30 | -7.93% | 4.91万 | | 2.28亿 | | 301235 | や康浩浄 | 29.72 | -7.90% | 15.14万 | | 4.42亿 | | 832278 | 鹿得医疗 | 11.23 | -7.88% | 9.33万 | | 1.07亿 | | 688212 | 澳华内镜 | 49.14 | -7.79% | 4.70万 | | 2.34亿 ...

Core Viewpoint - The recent stock trading activities of Aipeng Medical's executive, Li Qing, indicate a reduction in shareholding, which may reflect the company's current market sentiment and executive confidence in future performance [1][3]. Company Overview - Aipeng Medical's main business scope includes the production and sale of various medical devices and healthcare products, with a focus on pain management and respiratory products [2]. - As of December 31, 2024, the company's revenue from pain management products was 248 million yuan, accounting for 61.52% of total revenue, while revenue from nasal and upper airway products was 123 million yuan, making up 30.55% [2]. Executive Trading Activities - On August 12, 2025, Li Qing sold 14,900 shares at an average price of 35.00 yuan, resulting in a total transaction value of 521,500 yuan, reducing his holdings to 357,500 shares [1][3]. - Li Qing's previous transactions included selling 89,300 shares on August 8, 2025, at an average price of 37.94 yuan, totaling 3.39 million yuan [3]. - The total market capitalization of Aipeng Medical is reported to be 4.505 billion yuan [3].

爱朋医疗(300753.SZ)公告称，公司高级管理人员李庆于2025年8月8日至12日通过集中竞价方式减持公 司股份11.9174万股，占公司总股本的0.0945%，减持均价37.1130/股。减持后，李庆持有公司股份 35.7523万股，占总股本的0.2836%。 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-044 江苏爱朋医疗科技股份有限公司 关于公司高级管理人员减持计划实施完毕的公告 公司高级管理人员李庆先生保证向公司提供的信息内容真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 持股5%以上的股东XX保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于2025年7月17日披露了 《关于公司高级管理人员减持股份预披露的公告》（公告编号：2025-027），公司高 级管理人员李庆先生计划自上述公告披露之日起十五个交易日后的三个月内（即2025 年8月8日至2025年11月7日）以集中竞价方式减持公司股份不超过119,174股，占公司 总股本的比例为0.0945%。 | | | | 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 | | | | --- | --- | --- | --- | --- | --- | | 股东名称 | 减持方式 | 减持期间 | 减持均价 | ...